You are here:

carbetocin (Pabal)

Advice

following a full submission 

carbetocin (Pabal®) is not recommended for use within NHS Scotland.

Indication under review: For the prevention of uterine atony following delivery of the infant by Caesarean section under epidural or spinal anaesthesia.

A double-blind, randomised, controlled study in 377 women undergoing Caesarean section demonstrated a significant reduction in additional uterotonic treatment in women receiving carbetocin compared with oxytocin, although this result was not supported by two smaller double-blind, randomised, controlled studies.

The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

The licence holder has indicated their intention to resubmit.

Drug Details

Drug Name: carbetocin (Pabal)
SMC Drug ID: 309/06
Manufacturer: Ferring Pharmaceuticals Ltd
Indication: For the prevention of uterine atony following delivery of the infant by Caesarean section under epidural or spinal anaesthesia.
BNF Category:
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 15 January 2018

Back